Opexa Therapeutics, Inc. (OPXA) Misses Q2 EPS by 2c

Opexa Therapeutics, Inc. (NASDAQ: OPXA) reported Q2 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $307.7 thousand versus the consensus estimate of $330 thousand.

For earnings history and earnings-related data on Opexa Therapeutics, Inc. (OPXA) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Integra LifeSciences stock tumbles after cutting 2026 outlook
• RBC cuts Northrop Grumman rating on slower growth, cautious defense outlook